# (2023-02-02) Interpretable bilinear attention network with domain adaptation improves drugâ€“target prediction

## å…·æœ‰åŸŸé€‚åº”èƒ½åŠ›çš„å¯è§£é‡ŠåŒçº¿æ€§æ³¨æ„åŠ›ç½‘ç»œæ”¹å–„äº†è¯ç‰©é¶æ ‡é¢„æµ‹

|   |
|---|
|**ä½œè€…:** Peizhen Bai; Filip MiljkoviÄ‡; Bino John; Haiping Lu;|
|**æœŸåˆŠ: Nature Machine Intelligence ï¼ˆå‘è¡¨æ—¥æœŸ: 2023-02-02ï¼‰**|
|**æœŸåˆŠåˆ†åŒº:** ã…¤ã…¤ ã…¤ã…¤IF 18.8 ã…¤ã…¤ ã…¤ã…¤ ã…¤ã…¤ ã…¤ã…¤ ã…¤ã…¤ ã…¤ã…¤SCI Q1 ã…¤ã…¤ ã…¤ã…¤ ã…¤ã…¤ ã…¤ã…¤ ã…¤ã…¤ ã…¤ã…¤ä¸­ç§‘é™¢ å·¥ç¨‹æŠ€æœ¯1åŒº ã…¤ã…¤ ã…¤ã…¤|
|**æœ¬åœ°é“¾æ¥:** [Bai ç­‰ - 2023 - Interpretable bilinear attention network with domain adaptation improves drugâ€“target prediction.pdf](zotero://open-pdf/0_Q5LFPXN9)|
|**DOI:** [10.1038/s42256-022-00605-1](https://doi.org/10.1038/s42256-022-00605-1)|
|**æ‘˜è¦:**Predicting drug-target interaction is key for drug discovery. Recent deep learning-based methods show promising performance but two challenges remain: (i) how to explicitly model and learn local interactions between drugs and targets for better prediction and interpretation; (ii) how to generalize prediction performance on novel drug-target pairs from different distribution. In this work, we propose DrugBAN, a deep bilinear attention network (BAN) framework with domain adaptation to explicitly learn pair-wise local interactions between drugs and targets, and adapt on out-of-distribution data. DrugBAN works on drug molecular graphs and target protein sequences to perform prediction, with conditional domain adversarial learning to align learned interaction representations across different distributions for better generalization on novel drug-target pairs. Experiments on three benchmark datasets under both in-domain and cross-domain settings show that DrugBAN achieves the best overall performance against five state-of-the-art baselines. Moreover, visualizing the learned bilinear attention map provides interpretable insights from prediction results.|
|**æ ‡ç­¾:**|
|**ç¬”è®°æ—¥æœŸ:** 2024/10/24 17:00:05|

## ğŸ“œ ç ”ç©¶æ ¸å¿ƒ

---

> Tips: åšäº†ä»€ä¹ˆï¼Œè§£å†³äº†ä»€ä¹ˆé—®é¢˜ï¼Œåˆ›æ–°ç‚¹ä¸ä¸è¶³ï¼Ÿ

### âš™ï¸ å†…å®¹

æå‡ºDrugBANæ¡†æ¶ï¼Œç”¨æ¥é¢„æµ‹è¯ç‰©ä¸é¶æ ‡ä¹‹é—´çš„ç›¸äº’ä½œç”¨ï¼ˆDTIï¼‰ã€‚DrugBANé€šè¿‡åŒçº¿æ€§æ³¨æ„åŠ›ç½‘ç»œï¼ˆBANï¼‰æ˜¾å¼å­¦ä¹ è¯ç‰©å’Œé¶æ ‡ä¹‹é—´çš„å±€éƒ¨ç›¸äº’ä½œç”¨ï¼Œå¹¶é€šè¿‡é¢†åŸŸé€‚åº”æŠ€æœ¯æé«˜åœ¨æ–°é¢†åŸŸï¼ˆä¸åŒåˆ†å¸ƒçš„æ•°æ®ï¼‰ä¸Šçš„æ³›åŒ–èƒ½åŠ›ã€‚

### ğŸ’¡ åˆ›æ–°ç‚¹

DrugBANï¼šä¸€ç§æ·±åº¦åŒçº¿æ€§æ³¨æ„åŠ›ç½‘ç»œ(BAN)æ¡†æ¶ï¼Œå…·æœ‰åŸŸé€‚åº”åŠŸèƒ½ï¼Œå¯æ˜ç¡®å­¦ä¹ è¯ç‰©å’Œç›®æ ‡ä¹‹é—´çš„æˆå¯¹å±€éƒ¨ç›¸äº’ä½œç”¨ï¼Œå¹¶é€‚åº”åˆ†å¸ƒå¤–æ•°æ®ã€‚å®ƒåŸºäºè¯ç‰©åˆ†å­å›¾å’Œé¶è›‹ç™½åºåˆ—è¿›è¡Œé¢„æµ‹ï¼Œé€šè¿‡æ¡ä»¶åŸŸå¯¹æŠ—å­¦ä¹ æ¥å¯¹é½ä¸åŒåˆ†å¸ƒä¸­å­¦ä¹ åˆ°çš„ç›¸äº’ä½œç”¨è¡¨ç¤ºï¼Œä»¥ä¾¿æ›´å¥½åœ°æ¦‚æ‹¬æ–°çš„è¯ç‰©é¶ç‚¹å¯¹ã€‚

(i) é€šè¿‡åŒçº¿æ€§æ³¨æ„åŠ›æœºåˆ¶æ•è·è¯ç‰©å’Œç›®æ ‡ä¹‹é—´æˆå¯¹çš„å±€éƒ¨ç›¸äº’ä½œç”¨

(ii) é€šè¿‡å¯¹æŠ—åŸŸé€‚åº”æ–¹æ³•å¢å¼ºè·¨åŸŸæ³›åŒ–

(iii) é€šè¿‡åŒçº¿æ€§æ³¨æ„åŠ›æƒé‡è€Œä¸æ˜¯é»‘ç›’ç»“æœç»™å‡ºå¯è§£é‡Šçš„é¢„æµ‹ã€‚

CDANï¼šå°†å¯¹æŠ—ç½‘ç»œä¸å¤šçº¿æ€§è°ƒèŠ‚ç›¸ç»“åˆï¼Œç”¨äºå¯è½¬ç§»çš„è¡¨å¾å­¦ä¹ 

### ğŸ§© ä¸è¶³

å¹¶æ²¡æœ‰è€ƒè™‘åˆ°3Dç»“æ„çš„è›‹ç™½è´¨ï¼Œåªè€ƒè™‘äº†1Då’Œ2Dçš„è›‹ç™½è´¨ã€‚

## ğŸ” ç ”ç©¶å†…å®¹

---

### ğŸ’§ æ•°æ®

ä¸‰ä¸ªå…¬å…±DTIæ•°æ®é›†ï¼šBindingDBã€BioSNAPå’ŒHumanã€‚

### ğŸ‘©ğŸ»â€ğŸ’» æ–¹æ³•

1ã€é¦–å…ˆé€šè¿‡å›¾å·ç§¯ç½‘ç»œGCNå’Œå·ç§¯ç¥ç»ç½‘ç»œCNNåˆ†åˆ«å¯¹2Dè¯ç‰©åˆ†å­å›¾å’Œ1Dè›‹ç™½è´¨åºåˆ—ä¸­çš„å±€éƒ¨ç»“æ„è¿›è¡Œç¼–ç ã€‚

2ã€ç„¶åï¼Œå°†ç¼–ç çš„å±€éƒ¨è¡¨ç¤ºè¾“å…¥åˆ°BANæˆå¯¹çš„äº¤äº’æ¨¡å—æ¥å­¦ä¹ è¿™äº›è¯ç‰©å’Œè›‹ç™½è´¨è¡¨ç¤ºä¹‹é—´çš„å±€éƒ¨ç›¸äº’ä½œç”¨ã€‚ç”¨ä¸€ä¸ªå…¨è¿æ¥å±‚å¯¹å±€éƒ¨è”åˆè¡¨ç¤ºè¿›è¡Œè§£ç ä»¥è¿›è¡ŒDTIé¢„æµ‹ï¼ŒåŒæ—¶åˆ©ç”¨æˆå¯¹åŒçº¿æ€§æ³¨æ„åŠ›å›¾æ¥å¯è§†åŒ–æ¯ä¸ªå­ç»“æ„å¯¹æœ€ç»ˆé¢„æµ‹ç»“æœçš„è´¡çŒ®ï¼Œä»¥æé«˜å¯è§£é‡Šæ€§ã€‚

3ã€å¯¹äºè·¨åŸŸé¢„æµ‹ï¼Œä½¿ç”¨æ¡ä»¶åŸŸå¯¹æŠ—ç½‘ç»œï¼ˆCDANï¼‰å°†å­¦ä¹ çš„çŸ¥è¯†ä»æºåŸŸè½¬ç§»åˆ°ç›®æ ‡åŸŸä»¥å¢å¼ºè·¨åŸŸæ³›åŒ–ã€‚

### ğŸ”¬ å®éªŒ

åœ¨BindingDBã€BioSNAPå’ŒHumanè¿™ä¸‰ä¸ªå…¬å…±æ•°æ®é›†ä¸Šæµ‹è¯•åˆ†ç±»æ€§èƒ½ï¼ŒåŒ…æ‹¬ In-domain å’Œ Cross-domain ã€‚é€šè¿‡AUROCã€AUPRCã€Accuracyã€Sensitivityã€Specificityå¯¹æ¨¡å‹è¿›è¡Œè¯„ä¼°ã€‚

è¿˜è¿›è¡Œäº†æ¶ˆèå®éªŒ

### ğŸ“œ ç»“è®º

åœ¨åŸŸå†…DTIé¢„æµ‹ä¸­ï¼Œæ•°æ®é©±åŠ¨çš„è¡¨ç¤ºå­¦ä¹ å¯ä»¥æ•è·æ›´å¤šé‡è¦çš„ä¿¡æ¯ã€‚DrugBANè¿˜å¯ä»¥é€šè¿‡äº¤äº’æ¨¡å—æ•è·äº¤äº’æ¨¡å¼

DrugBANåœ¨æ³›åŒ–é¢†åŸŸé¢„æµ‹æ€§èƒ½æœ‰å¾ˆå¼ºçš„ä¼˜åŠ¿ã€‚

åŒçº¿æ€§æ³¨æ„åŠ›æ˜¯æ•è· DTI é¢„æµ‹äº¤äº’ä¿¡æ¯çš„æœ€æœ‰æ•ˆæ–¹æ³•ã€‚

DrugBANåœ¨åŸŸå†…å’Œè·¨åŸŸè®¾ç½®ä¸­å§‹ç»ˆå®ç°äº†æ”¹è¿› DTI é¢„æµ‹æ€§èƒ½ã€‚

DrugBANè¿˜å¯¹é¢„æµ‹ç»“æœæä¾›äº†å¯è§£é‡Šæ€§ã€‚

## ğŸ¤” ä¸ªäººæ€»ç»“

---

> Tips: ä½ å¯¹å“ªäº›å†…å®¹äº§ç”Ÿäº†ç–‘é—®ï¼Œä½ è®¤ä¸ºå¯ä»¥å¦‚ä½•æ”¹è¿›ï¼Ÿ

### ğŸ™‹â€â™€ï¸ é‡ç‚¹è®°å½•

In-domain classification assumes the testing data to be in the same domain as of the training data. Cross-Domain classification is a paradigm where testing data is from a different but related domain to the training data.

åŸŸå†…åˆ†ç±»å‡è®¾æµ‹è¯•æ•°æ®ä¸è®­ç»ƒæ•°æ®å±äºåŒä¸€åŸŸã€‚è·¨åŸŸåˆ†ç±»æ˜¯æŒ‡æµ‹è¯•æ•°æ®ä¸è®­ç»ƒæ•°æ®æ¥è‡ªä¸åŒä½†ç›¸å…³çš„é¢†åŸŸã€‚

### ğŸ“Œ å¾…è§£å†³

DeepMindçš„AlphaFoldåœ¨è›‹ç™½è´¨3Dç»“æ„é¢„æµ‹ä¸­å–å¾—äº†å·¨å¤§è¿›å±•ï¼Œè¿™ä¸€è¿›å±•ä¸ºåœ¨åŸºäºåŒ–å­¦åŸºå› ç»„å­¦çš„ DTI é¢„æµ‹ä¸­åˆ©ç”¨ 3D ç»“æ„ä¿¡æ¯æ‰“å¼€äº†å¤§é—¨ã€‚å°†DrugBANå’Œè¿™äº›æ•°æ®é›†ç»“åˆæ˜¯æœªæ¥ä¸€ä¸ªå¾ˆå¥½çš„ç ”ç©¶æ–¹å‘ã€‚

### ğŸ’­ æ€è€ƒå¯å‘